Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands

Journal of Medicinal Chemistry
Ziqian WangZhichao Zhang

Abstract

Proteolysis targeting chimera (PROTAC) recruits an E3 ligase to a target protein to induce its ubiquitination and subsequent degradation. We reported success in the development of two PROTACs (C3 and C5) that potently and selectively induce the degradation of Mcl-1 and Bcl-2 (DC50 = 0.7 and 3.0 μM), respectively, by introducing the E3 ligase cereblon-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitors S1-6 and Nap-1 with micromolar-range affinity. C3-induced Mcl-1 ubiquitination translated into much more lethality in Mcl-1-dependent H23 cells than the most potent Mcl-1 occupancy-based inhibitor A-1210477 with nanomolar-range affinity. Moreover, structure-activity relationship analysis and molecular dynamic simulations discovered the structural basis for turning nonselective or promiscuous Bcl-2 family ligands into selective PROTACs. C3 and C5 exhibited reversible depletion in living cells, which provides a new potent toolkit for gain-of-function studies to probe the dynamic roles of Bcl-2 and Mcl-1 in apoptosis networks.

References

Jul 5, 2005·Current Opinion in Structural Biology·Daniel P Ryan, Jacqueline M Matthews
Jan 13, 2010·Protein Science : a Publication of the Protein Society·Emiko FireAmy E Keating
Jan 12, 2011·Journal of Medicinal Chemistry·Raymond J PatchMicheal D Gaul
Dec 4, 2012·Trends in Cell Biology·Abdel AouacheriaJ Marie Hardwick
Feb 21, 2013·Nature Chemistry·Valeria AzzaritoAndrew J Wilson
May 16, 2013·Proceedings of the National Academy of Sciences of the United States of America·John HinesCraig M Crews
Apr 17, 2014·Chemical Reviews·Lech-Gustav MilroyChristian Ottmann
Aug 12, 2014·Nature Structural & Molecular Biology·Philip P ChamberlainBrian E Cathers
Feb 14, 2015·Journal of Medicinal Chemistry·Milan BrunckoAndrew J Souers
Jun 3, 2015·ACS Chemical Biology·Michael ZengerleAlessio Ciulli
Jun 9, 2015·Chemistry & Biology·Jing LuCraig M Crews
Jun 16, 2015·Nature Chemical Biology·Daniel P BondesonCraig M Crews
Aug 19, 2015·Nature Chemical Biology·Raymond J Deshaies
Nov 7, 2015·Trends in Biochemical Sciences·Abdel AouacheriaJ Marie Hardwick
Jan 13, 2016·Angewandte Chemie·Momar Toure, Craig M Crews
Mar 17, 2016·Journal of Medicinal Chemistry·Ziqian WangZhichao Zhang
Jun 9, 2016·Proceedings of the National Academy of Sciences of the United States of America·Kanak RainaKevin G Coleman
Nov 26, 2016·Nature Reviews. Drug Discovery·Ashton C Lai, Craig M Crews
Jan 7, 2017·ACS Central Science·Honorine LebraudTom D Heightman
Jan 29, 2017·Current Opinion in Structural Biology·Xavier Lucas, Alessio Ciulli
Mar 14, 2017·Nature Chemical Biology·Morgan S GaddAlessio Ciulli
Apr 19, 2017·Angewandte Chemie·David RemillardJames E Bradner
Jun 22, 2017·Chemical Communications : Chem Comm·Caroline M RobbSandeep Rana
Jun 27, 2017·Cell Chemical Biology·Philipp M Cromm, Craig M Crews
Nov 14, 2017·Cell Chemical Biology·George M BurslemCraig M Crews
Nov 14, 2017·Cell Chemical Biology·Hai-Tsang HuangNathanael S Gray
Nov 14, 2017·Cell Chemical Biology·Daniel P BondesonCraig M Crews
Dec 19, 2017·Nature Chemical Biology·Calla M OlsonNathanael S Gray
Aug 18, 2018·ACS Chemical Biology·Christian SteinebachJan Krönke
May 24, 2019·Journal of Medicinal Chemistry·James W PapatzimasDarren J Derksen
Jan 1, 2018·Cell Death and Differentiation·Francesca Pentimalli

❮ Previous
Next ❯

Citations

Nov 23, 2019·Chemical Communications : Chem Comm·Xuan ZhangGuangrong Zheng
Feb 23, 2020·Future Medicinal Chemistry·Xuan ZhangGuangrong Zheng
Apr 10, 2020·Future Medicinal Chemistry·Yichao WanTingting Liu
May 21, 2020·Future Medicinal Chemistry·Xingui LiuDaohong Zhou
Jul 29, 2020·Journal of Hematology & Oncology·Yonghan HeDaohong Zhou
May 15, 2020·Journal of Hematology & Oncology·Xin Li, Yongcheng Song
Dec 31, 2019·Signal Transduction and Targeted Therapy·Xiuyun SunYu Rao
Feb 26, 2020·Cell Death and Differentiation·Tirta Mario DjajawiMark F van Delft
Feb 1, 2020·Molecular Cell·Rati VermaRaymond J Deshaies
Jan 29, 2021·Journal of Medicinal Chemistry·Maha HanafiNouri Neamati
Dec 15, 2020·Journal of Hematology & Oncology·Arnold BolomskyJo Caers
Apr 23, 2021·Journal of Hematology & Oncology·Haolan WangYongheng Chen
May 19, 2021·Cell Chemical Biology·Kusal T G Samarasinghe, Craig M Crews
May 21, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Linlin ZhangXiangxuan Zhao
Jan 1, 2020·Exploration of Targeted Anti-tumor Therapy·Peiyi ZhangGuangrong Zheng
Aug 6, 2021·Frontiers in Cell and Developmental Biology·Jing LiuWenyi Wei
Aug 3, 2021·International Journal of Biological Macromolecules·Pooja MittalIndrakant Kumar Singh
Aug 20, 2021·European Journal of Medicinal Chemistry·Chao WangDongming Xing
Aug 17, 2020·Cell Chemical Biology·Dhanusha A Nalawansha, Craig M Crews
Oct 30, 2019·Biochemistry·Xiuyun Sun, Yu Rao
Sep 25, 2020·Journal of Chemical Information and Modeling·Michael L DrummondChristopher I Williams
Dec 21, 2019·ACS Medicinal Chemistry Letters·Philip P ChamberlainLawrence G Hamann
Sep 14, 2021·Biochemical Society Transactions·Erinna F Lee, W Douglas Fairlie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.